TajikistanTuberculosis profile
Population  2015 8.5 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.22 (0.15–0.31) 2.6 (1.8–3.6)
Mortality (HIV+TB only) 0.034 (<0.01–0.13) 0.41 (0.01–1.5)
Incidence  (includes HIV+TB) 7.4 (5.7–9.3) 87 (67–109)
Incidence (HIV+TB only) 0.2 (0.15–0.25) 2.4 (1.8–3)
Incidence (MDR/RR-TB)** 1.9 (1.5–2.2) 22 (18–26)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females <0.01 (0–<0.01) 3.4 (2.5–4.3) 3.4 (2.5–4.3)
Males <0.01 (<0.01–<0.01) 4 (3.1–4.9) 4 (3.1–4.9)
Total <0.01 (<0.01–<0.01) 7.4 (6.5–8.3) 7.4 (5.7–9.3)
TB case notifications, 2015  
Total cases notified 6 232
Total new and relapse 5 894
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 95%
          - % pulmonary 73%
          - % bacteriologically confirmed among pulmonary 70%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.04 (0.02–0.05)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 152 3%
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 300
(1 200–1 300)
Estimated % of TB cases with MDR/RR-TB 14% (12–15) 77% (73–80)  
% notified tested for rifampicin resistance 50% 60% 3 223
MDR/RR-TB cases tested for resistance to second-line drugs   418
Laboratory-confirmed cases MDR/RR-TB: 675, XDR-TB: 54
Patients started on treatment **** MDR/RR-TB: 636, XDR-TB: 46
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 89% 5 149
Previously treated cases, excluding relapse, registered in 2014 82% 355
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 60% 625
XDR-TB cases started on second-line treatment in 2013 75% 4
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 70%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 29
Funding source: 24% domestic, 35% international, 41% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data